Tianjin Pharmaceutical Da Ren Tang Group (600329) Fundamentals 2026 — P/E 13.3x, Revenue Analysis | SniperIQ
Tianjin Pharmaceutical Da Ren Tang Group (600329) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥21.5B, trading at ¥37.69 on the SHH. This SniperIQ fundamentals page covers Tianjin Pharmaceutical Da Ren Tang Group's valuation (P/E 13.3x, P/B 3.9x), profitability (net margin 43.8%), revenue (¥4.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Tianjin Pharmaceutical Da Ren Tang Group's market cap?
Tianjin Pharmaceutical Da Ren Tang Group (600329) has a market capitalization of approximately ¥21.5B, trading at ¥37.69 on the SHH. Market cap moves with the live share price.
What is Tianjin Pharmaceutical Da Ren Tang Group's P/E ratio?
Tianjin Pharmaceutical Da Ren Tang Group's trailing twelve-month P/E ratio is 13.3x, with a price-to-book (P/B) of 3.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Tianjin Pharmaceutical Da Ren Tang Group?
Tianjin Pharmaceutical Da Ren Tang Group runs a net profit margin of 43.8%, a gross margin of 75.0%, and an operating margin of 49.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Tianjin Pharmaceutical Da Ren Tang Group generate?
Tianjin Pharmaceutical Da Ren Tang Group reported revenue of ¥4.9B for fiscal year 2025, with net income of ¥2.1B and earnings per share (EPS) of 2.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Tianjin Pharmaceutical Da Ren Tang Group pay a dividend?
Tianjin Pharmaceutical Da Ren Tang Group offers a trailing dividend yield of about 6.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Tianjin Pharmaceutical Da Ren Tang Group financially healthy?
Tianjin Pharmaceutical Da Ren Tang Group carries a debt-to-equity ratio of 0.01x and a current ratio of 2.16x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Tianjin Pharmaceutical Da Ren Tang Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tianjin Pharmaceutical Da Ren Tang Group (600329) the key facts are: market cap ¥21.5B, P/E 13.3x, revenue ¥4.9B, 52-week range 34.7-50.97. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Tianjin Pharmaceutical Da Ren Tang Group's full fundamentals live
Get Tianjin Pharmaceutical Da Ren Tang Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.